6,497 Shares of VanEck Pharmaceutical ETF $PPH Bought by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. purchased a new position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) during the third quarter, Holdings Channel reports. The firm purchased 6,497 shares of the company’s stock, valued at approximately $711,000.

Other large investors also recently bought and sold shares of the company. TD Waterhouse Canada Inc. raised its holdings in shares of VanEck Pharmaceutical ETF by 130.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 230 shares of the company’s stock worth $25,000 after acquiring an additional 130 shares during the period. Arkadios Wealth Advisors increased its holdings in shares of VanEck Pharmaceutical ETF by 1.8% during the 1st quarter. Arkadios Wealth Advisors now owns 8,447 shares of the company’s stock worth $877,000 after buying an additional 150 shares during the last quarter. Axxcess Wealth Management LLC increased its holdings in shares of VanEck Pharmaceutical ETF by 2.0% during the 3rd quarter. Axxcess Wealth Management LLC now owns 9,741 shares of the company’s stock worth $1,066,000 after buying an additional 188 shares during the last quarter. IFP Advisors Inc raised its position in shares of VanEck Pharmaceutical ETF by 115.7% during the 2nd quarter. IFP Advisors Inc now owns 537 shares of the company’s stock valued at $59,000 after buying an additional 288 shares during the period. Finally, Blue Chip Partners LLC raised its position in shares of VanEck Pharmaceutical ETF by 11.8% during the 1st quarter. Blue Chip Partners LLC now owns 3,889 shares of the company’s stock valued at $404,000 after buying an additional 411 shares during the period.

VanEck Pharmaceutical ETF Stock Performance

PPH opened at $122.11 on Thursday. VanEck Pharmaceutical ETF has a one year low of $92.60 and a one year high of $122.13. The stock has a market capitalization of $1.12 billion, a PE ratio of 20.21 and a beta of 0.45. The business’s 50 day moving average price is $112.77 and its 200 day moving average price is $108.17.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Stockholders of record on Thursday, October 1st were issued a dividend of $0.36 per share. The ex-dividend date was Thursday, October 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.2%. This is a drop from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.